MABWELL-B(02493): 9MW1911 will present the latest clinical data in poster form at the 2026 European Respiratory Society Annual Meeting (ERS).

MABWELL-B (02493) announced that the company will present clinical research data from the Phase Ib/IIa study of 9MW1911 for moderate to severe COPD patients with a history of smoking in the form of a poster at the 2026 European Respiratory Society (ERS) Annual Meeting, which will be held in Barcelona from September 5 to September 9, 2026. Preliminary efficacy results indicate that 9MW1911 shows promising efficacy signals in reducing acute exacerbations of COPD, with a significant downward trend in the annualized incidence of acute exacerbations in the moderate to severe COPD group receiving high to moderate doses. There remains uncertainty regarding whether the clinical trial results can support the submission of a new drug application, whether it will ultimately receive marketing approval, and when such approval may be granted. Investors are advised to be aware of the potential investment risks, and the company will fulfill its obligation of timely information disclosure regarding subsequent developments in accordance with relevant regulations.